Ambeed.cn

首页 / / / / GSK503

GSK503 {[allProObj[0].p_purity_real_show]}

货号:A432623 Ambeed 开学季,买赠积分,赢豪礼

GSK-503 是一种强效的 EZH2 抑制剂,具有潜在的抗癌活性。

GSK503 化学结构 CAS号:1346572-63-1
GSK503 化学结构
CAS号:1346572-63-1
GSK503 3D分子结构
CAS号:1346572-63-1
GSK503 化学结构 CAS号:1346572-63-1
GSK503 3D分子结构 CAS号:1346572-63-1
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

GSK503 纯度/质量文件 产品仅供科研

货号:A432623 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

JACS Au, 2024. Ambeed. [ A148168 ]
JMC, 2024. Ambeed. [ A187643 ]
JMC, 2024. Ambeed. [ A341145 , A633512 , A607865 , A167774 ]
Biomacromolecules, 2024. Ambeed. [ A110759 ]
Biomacromolecules, 2024. Ambeed. [ A203543 ]
更多 >
产品名称 BET bromodomain BRPF CBP/beta-catenin p300/CBP 其他靶点 纯度
MS436 ++

BRD4 (1), Ki: <0.085 μM

BRD4 (2), Ki: 0.34 μM

{[allProObj[0].p_purity_real_show]}
CPI-203 +++

BRD4, IC50: 37 nM

{[allProObj[0].p_purity_real_show]}
GSK1324726A +++

BRD4, IC50: 22 nM

BRD2, IC50: 31 nM

{[allProObj[0].p_purity_real_show]}
PFI-1 ++

BRD4, IC50: 0.22 μM

BRD2, IC50: 98 nM

{[allProObj[0].p_purity_real_show]}
Apabetalone +

BD2, IC50: 0.51 μM

{[allProObj[0].p_purity_real_show]}
(+)-JQ1 +++

BRD4 (2), IC50: 33 nM

BRD4 (1), IC50: 77 nM

{[allProObj[0].p_purity_real_show]}
I-BET151 +

BRD4, IC50: 0.5 μM

BRD3, IC50: 0.25 μM

{[allProObj[0].p_purity_real_show]}
Molibresib +++

BET proteins, IC50: 35 nM

{[allProObj[0].p_purity_real_show]}
I-BRD9 +++

BRD9, pIC50: 7.3

BRD4, pIC50: 5.3

{[allProObj[0].p_purity_real_show]}
BI-7273 ++++

BRD7, IC50: 117 nM

BRD9, IC50: 19 nM

{[allProObj[0].p_purity_real_show]}
Pelabresib +++

BRD4-BD1, IC50: 39 nM

{[allProObj[0].p_purity_real_show]}
ARV-825 +++

BRD4 BD2, Kd: 28 nM

BRD4 BD1, Kd: 90 nM

{[allProObj[0].p_purity_real_show]}
Birabresib {[allProObj[0].p_purity_real_show]}
BI 2536 +++

BRD4, Kd: 37 nM

c-Myc {[allProObj[0].p_purity_real_show]}
Bromosporine ++

BRD2, IC50: 0.29 μM

BRD9, IC50: 0.122 μM

++++

CECR2, IC50: 17 nM

{[allProObj[0].p_purity_real_show]}
XMD8-92 ++

BRD4 (1), Kd: 170 nM

{[allProObj[0].p_purity_real_show]}
Mivebresib {[allProObj[0].p_purity_real_show]}
BI-9564 ++++

BRD9, Kd: 5.9 nM

BRD7, Kd: 73 nM

++

CECR2, Kd: 77 nM

{[allProObj[0].p_purity_real_show]}
AZD5153 6-Hydroxy-2-naphthoic acid ++++

FL-BRD4, IC50: 5 nM

{[allProObj[0].p_purity_real_show]}
PLX51107 ++++

BRD4 BD2, Kd: 1.7 nM

BRD3 BD1, Kd: 2.1 nM

{[allProObj[0].p_purity_real_show]}
FL-411 +

BRD4(1), IC50: 0.43 μM

{[allProObj[0].p_purity_real_show]}
ABBV-744 {[allProObj[0].p_purity_real_show]}
dBET6 ++++

BRD4, IC50: 14 nM

{[allProObj[0].p_purity_real_show]}
dBET1 ++++

BRD4, IC50: 20 nM

{[allProObj[0].p_purity_real_show]}
MZ1 ++++

Brd3(BD2), Kd: 13 nM

Brd2(BD2), Kd: 62 nM

{[allProObj[0].p_purity_real_show]}
dBET57 +

BRD4BD1, DC50: 500 nM

{[allProObj[0].p_purity_real_show]}
SF2523 +

BRD4, IC50: 241 nM

DNA-PK {[allProObj[0].p_purity_real_show]}
INCB054329 ++++

BRD3-BD1, IC50: 9 nM

BRD4-BD1, IC50: 119 nM

{[allProObj[0].p_purity_real_show]}
INCB-057643 {[allProObj[0].p_purity_real_show]}
(E/Z)-ZL0420 +++

BRD4 BD1, IC50: 27 nM

BRD4 BD2, IC50: 32 nM

{[allProObj[0].p_purity_real_show]}
BMS-986158 {[allProObj[0].p_purity_real_show]}
BRD4 Inhibitor-10 ++++

BRD4-BD2, IC50: 41 nM

BRD4-BD1, IC50: 5 nM

{[allProObj[0].p_purity_real_show]}
A1874 {[allProObj[0].p_purity_real_show]}
Y06036 ++

BRD4 (1), Kd: 82 nM

{[allProObj[0].p_purity_real_show]}
Alobresib NF-κB {[allProObj[0].p_purity_real_show]}
ODM-207 {[allProObj[0].p_purity_real_show]}
GSK778 +++

BRD2-BD1, IC50: 75nM

BRD4-BD1, IC50: 143 nM

{[allProObj[0].p_purity_real_show]}
SRX3207 +

BRD41, IC50: 3070 nM

BRD42, IC50: 3070 nM

Syk {[allProObj[0].p_purity_real_show]}
GSK046 +++

BRD4BD2, IC50: 214 nM

BRD3BD2, IC50: 98 nM

{[allProObj[0].p_purity_real_show]}
GSK620 {[allProObj[0].p_purity_real_show]}
Thalidomide-NH-C4-NH-Boc {[allProObj[0].p_purity_real_show]}
Trotabresib {[allProObj[0].p_purity_real_show]}
NHWD-870 {[allProObj[0].p_purity_real_show]}
CFT8634 ++++

BRD9, DC50: 3 nM

{[allProObj[0].p_purity_real_show]}
GSK2801 ++

BAZ2B, Kd: 136 nM

BAZ2A, Kd: 257 nM

{[allProObj[0].p_purity_real_show]}
KG-501 {[allProObj[0].p_purity_real_show]}
UNC 669 +

L3MBTL4, IC50: 6 μM

L3MBTL3, IC50: 35 μM

{[allProObj[0].p_purity_real_show]}
PFI-3 +++

SMARCA4, Kd: 55 nM

SMARCA2A, Kd: 72 nM

{[allProObj[0].p_purity_real_show]}
UNC1215 +++

L3MBTL3, IC50: 120 nM

L3MBTL3- D274A, IC50: 3.5 μM

{[allProObj[0].p_purity_real_show]}
EED226 ++

EED, Kd: 82 nM

PRC2, Kd: 114 nM

{[allProObj[0].p_purity_real_show]}
BRD9539 {[allProObj[0].p_purity_real_show]}
UNC926 +

L3MBTL1, Kd: 3.9 μM

{[allProObj[0].p_purity_real_show]}
666-15 ++

CREB, IC50: 81 nM

{[allProObj[0].p_purity_real_show]}
UNC6852 +

EED, IC50: 247 nM

{[allProObj[0].p_purity_real_show]}
BAZ1A-IN-1 +

BAZ1A, Kd: 0.52 μM

{[allProObj[0].p_purity_real_show]}
PFI-4 ++

BRPF1, IC50: 80 nM

BRPF2, IC50: 7.9 μM

{[allProObj[0].p_purity_real_show]}
OF-1 ++

BRPF2, Kd: 500 nM

BRPF1B, Kd: 100 nM

{[allProObj[0].p_purity_real_show]}
GSK-5959 ++

BRPF3, pIC50: 7.1

BRPF2, pIC50: 5.2

{[allProObj[0].p_purity_real_show]}
GSK6853 ++++

BRPF1, pIC50: 8.1

{[allProObj[0].p_purity_real_show]}
NI-42 ++++

BRPF1, IC50: 48 nM

BRPF3, IC50: 260 nM

{[allProObj[0].p_purity_real_show]}
E-7386 +++

CBP/beta-catenin, IC50: 0.0484 μM

{[allProObj[0].p_purity_real_show]}
I-CBP112 ++

p300, Kd: 167 nM

CBP, Kd: 151 nM

{[allProObj[0].p_purity_real_show]}
Histone Acetyltransferase Inhibitor II +

p300, IC50: 5 μM

{[allProObj[0].p_purity_real_show]}
C646 +

p300/CBP, Ki: 400 nM

{[allProObj[0].p_purity_real_show]}
Anacardic Acid +

p300/CBP, IC50: 8.5 μM

PCAF, IC50: 5 μM

{[allProObj[0].p_purity_real_show]}
SGC-CBP30 ++++

CREBBP, IC50: 21 nM

EP300, IC50: 38 nM

{[allProObj[0].p_purity_real_show]}
Nordihydroguaiaretic acid HER2,IGF-1R {[allProObj[0].p_purity_real_show]}
Curcumin +

p300, IC50: ~25 μM

Nrf2,Ferroptosis,NF-κB {[allProObj[0].p_purity_real_show]}
PF-CBP1 HCl ++

CREBBP, IC50: 125nM

p300/CBP, IC50: 363nM

{[allProObj[0].p_purity_real_show]}
CPI-637 +++

CBP, IC50: 0.03 μM

EP300, IC50: 0.051 μM

{[allProObj[0].p_purity_real_show]}
Foscenvivint β-catenin {[allProObj[0].p_purity_real_show]}
A-485 ++

p300 HAT, IC50: 0.06 μM

{[allProObj[0].p_purity_real_show]}
GNE-781 +

BRD4(1), IC50: 5100 nM

++++

CBP, IC50: 0.94 nM

{[allProObj[0].p_purity_real_show]}
NEO2734 +++

BET, IC50: <30 nM

+++

p300/CBP, IC50: <30 nM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。
产品名称 Histone Methyltransferase 其他靶点 纯度
BRD4770 {[allProObj[0].p_purity_real_show]}
UNC1999 +++

EZH1, IC50: 45 nM

EZH2, IC50: 2 nM

{[allProObj[0].p_purity_real_show]}
EPZ005687 ++

EZH2, Ki: 24 nM

{[allProObj[0].p_purity_real_show]}
EPZ015666 +++

PRMT5, Ki: 5 nM

{[allProObj[0].p_purity_real_show]}
3-Deazaneplanocin A HCl ++++

S-adenosylhomocysteine hydrolase, Ki: 50 pM

{[allProObj[0].p_purity_real_show]}
EPZ6438 +++

EZH2, Ki: 2.5 nM

EZH2, IC50: 11 nM

{[allProObj[0].p_purity_real_show]}
GSK126 ++

EZH2, IC50: 9.9 nM

{[allProObj[0].p_purity_real_show]}
MI-3 +

Menin-MLL, IC50: 648 nM

{[allProObj[0].p_purity_real_show]}
MM-102 ++

MLL1, IC50: 0.4 μM

{[allProObj[0].p_purity_real_show]}
EI1 ++

Ezh2 (wild-type), IC50: 15 nM

EZH2 (Y641F), IC50: 13 nM

{[allProObj[0].p_purity_real_show]}
SGC0946 ++++

DOT1L, IC50: 0.3 nM

{[allProObj[0].p_purity_real_show]}
PFI-2 HCl ++++

SETD7, Ki: 0.33 nM

SETD7, IC50: 2 nM

{[allProObj[0].p_purity_real_show]}
Pinometostat ++++

DOT1L, Ki: 80 pM

{[allProObj[0].p_purity_real_show]}
EPZ004777 +++

DOT1L, IC50: 0.4 nM

{[allProObj[0].p_purity_real_show]}
Entacapone ++

COMT, IC50: 151 nM

{[allProObj[0].p_purity_real_show]}
UNC0379 +

SETD8, IC50: 7.9 μM

{[allProObj[0].p_purity_real_show]}
Menin-MLL inhibitor MI-2 +

Menin-MLL, IC50: 446 nM

{[allProObj[0].p_purity_real_show]}
GSK343 +++

EZH1, IC50: 240 nM

EZH2, IC50: 4 nM

{[allProObj[0].p_purity_real_show]}
BIX-01294 3HCl +

G9a, IC50: 2.7 μM

{[allProObj[0].p_purity_real_show]}
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。

GSK503 生物活性

描述 GSK-503 is a potent EZH2 inhibitor with potential anticancer activity.

GSK503 参考文献

[1]Zingg D, Debbache J, et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nat Commun. 2015 Jan 22;6:6051.

GSK503 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.90mL

0.38mL

0.19mL

9.49mL

1.90mL

0.95mL

18.99mL

3.80mL

1.90mL

GSK503 技术信息

CAS号1346572-63-1
分子式C31H38N6O2
分子量 526.672
别名
运输蓝冰
存储条件

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 45 mg/mL(85.44 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。